PROCEPT BioRobotics Q2 2026: HYDROS Momentum with a Profit Path in Sight, PRCT Navigates Tariffs and Guidance
In this quarterly briefing, the microcosm of a growth-stage medical device company plays out through revenue drivers, margin tweaks, and strategic bets. Ticker PRCT remains the lens; EPS discussions are quiet for now, but the revenue forecast and long-run path are loud enough to draw attention from investors watching the BPH robotics space.
Executive snapshot: what happened in Q2 2026
PROCEPT BioRobotics Corp. (Nasdaq: PRCT) reported second-quarter 2026 results that underscore growth momentum even as the company still operates in a loss frame. Total revenue reached $94.5 million, up 19% versus the prior year period. U.S. revenue was $83.4 million, representing a 20% year-over-year increase, while international revenue totaled $11.1 million, up 15%. The gross margin clocked in at 66%, modestly higher than the prior-year period and the first quarter of 2026, aided by pricing discipline and a $2.9 million tariff refund.
Net loss was $26.9 million for the quarter, with adjusted EBITDA a loss of $11.3 million. On the balance sheet, the company reported roughly $231 million in cash, cash equivalents and restricted cash as of June 30, 2026.
Revenue drivers and product mix
The company highlighted several drivers behind the quarterly strength:
- U.S. handpiece and consumable revenue contributed meaningfully to the top line, though the quarter’s gains came with broader system activity as well.
- 61%+ of U.S. activity centered on HYDROS systems—delivered as 65 units in total during the quarter, including replacements. The HYDROS platform continues to be the core growth engine, with pricing discipline supporting margin stability.
- International revenue ticked higher, reflecting continued cross-border adoption of Aquablation therapy as the company navigates regional demand.
- A tariff refund of $2.9 million helped modestly boost gross margin in the quarter.
Margin dynamics, expenses, and the profitability trajectory
Gross margin improved to 66% from 65% in the prior year period and 65% in Q1 2026, underscoring the impact of pricing actions and a favorable tariff adjustment. Operating expenses rose to $89.8 million from $73.9 million a year earlier, reflecting continued investment in the commercial organization, ongoing innovation across the BPH platform, and costs tied to enrollment and follow-up in the WATER IV Prostate Cancer trial.
Net loss widened to $26.9 million for the quarter, and adjusted EBITDA was a $11.3 million loss, signaling that the company remains in an investment phase as it scales its commercial and clinical programs. Investors will be watching how the operating leverage develops as AQUABlation-related adoption expands and as the WATER IV study progresses.
Guidance and forward-looking view
For full-year 2026, PROCEPT reaffirmed its revenue forecast in the range of $390 million to $410 million, implying growth of roughly 27% to 33% versus the prior year. The company did not publish a formal EPS figure in this release, and there was no explicit “earnings surprise” noted; instead, the focus remains on top-line growth, margin discipline, and the execution of its commercial and clinical milestones. Analysts and investors will likely compare the trajectory against expectations embedded in EPS consensus estimates as they surface, given that the GAAP EPS impact will depend on operating leverage and the pace of cost containment alongside revenue growth.
Strategic context: what this portends for PRCT and peers
The narrative around PROCEPT continues to hinge on HYDROS adoption, replacement cycles, and the integration of robotic-assisted, AI-enhanced imaging with real-time guidance. The WATER IV enrollment progress and the updated American Urological Association guidelines that bolster Aquablation therapy provide a tailwind for near-term uptake. For peers in the urology robotics space, PROCEPT’s quarterly performance reinforces a pattern: growth is achievable through a combination of product velocity, international expansion, and thoughtful pricing that preserves margin in a high-investment environment.
From a competitive perspective, the combination of tariff refunds and a deliberate cost structure means investors will watch how durable gross margins remain as R&D and sales expansion continue. If HYDROS placements accelerate beyond current cadence, the revenue mix could tilt further toward consumables and replacement cycles, which often offer higher long-run gross margins versus initial system sales. The sector’s longer arc remains about translating patient-volume growth into sustainable profitability; PROCEPT’s progress will be a useful signal for investors assessing the feasibility of a profitable scale in medical robotics.
Takeaways
Q2 2026 demonstrates notable top-line momentum for PRCT, driven by HYDROS system activity, a strengthening U.S. revenue base, and international expansion. The gross margin improvement and a tariff refund help cushion operating losses, but the company remains in the investment phase as it scales its clinical programs and commercial footprint. The reaffirmed revenue forecast provides a clear anchor for the stock as analysts begin to model potential paths to profitability, with EPS and EPS consensus debates likely to hinge on operating leverage once scale reaches a sustainable level. For investors, the key questions are: will HYDROS-driven growth translate into meaningful operating margin expansion, and how quickly can PROCEPT convert top-line gains into meaningful earnings per share on a sustained basis?
In the near term, PRCT’s trajectory will be a reference point for peers pursuing a similar blend of capital-light clinical strategy and capital-intensive product deployment. The next chapters—WATER IV enrollment outcomes, AQUABlation adoption in updated guidelines, and the cadence of international revenue—will be the telltale signs of whether this story shifts from growth narrative to profitability narrative.